ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has announced today that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via
ImmuPharma’s Tim McCarthy discusses completion of their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the completion of the Lupuzor™ pivotal phase III study and an initiation of a follow up study. Tim explains the
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the
We look at 19 stocks primed to deliver major events in their career By the Shares team Investors are spoiled for choice when it comes to small cap stocks with
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of
ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus. Key highlights included: 200 patients
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has this morning provided DirectorsTalk with an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor(TM),
ImmuPharma’s Tim McCarthy discusses their interim results & initiating Lupuzor’s regulatory submission in this exclusive interview with DirectorsTalk
ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. in February 2016. As
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
